The new guidelines are yet another sign that GLP-1 drugs like Ozempic are likely to continue soaring in popularity as a ...

Ozempic, Wegovy, Mounjaro, Zepbound-this new wave of medications boosts levels of the hormone GLP-1, dramatically shrinking ...

Sign up here to get The Boston Globe’s latest food stories delivered to your inbox once a week. In April, I went public with ...

After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April. The 25- year-old who lives in New York ...

Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.

The company, Novo Nordisk, said Friday that prescription-only injectable pens for both drugs will be sold at more than 500 Costco pharmacies in the United States. Executive members and people with ...

Among patients without type 2 diabetes, GLP-1 drug use before weight-loss surgery increased to 23% in the fourth quarter of ...

Eli Lilly (NYSE:LLY) has decided to stop one of its obesity drug combination trials, pressing pause on a study that paired ...

“Our findings suggest that GLP-1 receptor agonists may offer benefits beyond their effects on weight and glucose control, particularly for cardiovascular and psychiatric outcomes in people with ...

Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand ...

(Reuters) -Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much ...

After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.